Drugs / p946/tet-p
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00003224 | Feb 1996 → Aug 2000 | cutaneous melanoma | University of Virginia | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | p946/tet-p | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00003224 ↗ |
| Known as | peptide 946-tetanus peptide conjugate melanoma vaccine | “peptide 946-tetanus peptide conjugate melanoma vaccine” NCT00003224 ↗ |
| Modality | Vaccine | “peptide 946-tetanus peptide conjugate melanoma vaccine” NCT00003224 ↗ |
| Route | Subcutaneous | “Arm V: Patients receive peptide 946-tetanus peptide conjugate emulsified with QS21 SQ.” NCT00003224 ↗ |